Compare Wahed FTSE USA Shariah ETF (HLAL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Wahed FTSE USA Shariah ETF trades at $74.41 (market cap $997.79M), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 5× Wahed FTSE USA Shariah ETF's market cap, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Wahed FTSE USA Shariah ETF for 67 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| HLAL | TVTX | |
|---|---|---|
Market Cap | $997.79M | $5.02B |
Volume | 65,395 | 2,060,842 |
Sector | Sector/Thematic | Health |
52-Week High | $76.54 | $67.52 |
52-Week Low | $57.46 | $26.79 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $75.90, showing modest daily gains of 0.13% with a bullish technical outlook supported by moving averages. The stock faces resistance near $77-78 while finding support at $75-74 levels. Key technical indicators show mixed signals with RSI suggesting potential overbought conditions on shorter timeframes.
Investment outlook remains data-dependent given limited fundamental information availability. The technical setup suggests near-term upside potential if resistance levels are breached, though momentum indicators warrant caution. Investors should await upcoming financial disclosures for clearer fundamental assessment.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
